Anika Therapeutics Inc (ANIK)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $179.50M
Last updated: Nov 17, 2026 at 11:04 AM ET
Anika Therapeutics Inc (ANIK) Stock Forecast
Analysts expect Anika Therapeutics (ANIK) to earn $0.10 per share in the fiscal year ending Dec 31, 2026, on revenue of $121.58M. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is $0.19.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 90.0% and revenue estimates rise 4.2%.
- Fiscal year ending Dec 31, 2026
- $0.10
- EPS consensus, revenue $121.58M
- Fiscal year ending Dec 31, 2027
- $0.19
- EPS consensus, revenue $126.72M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.10 | $0.10 to $0.10 | 1 | $121.58M | $120.70M to $122.47M | 2 |
| Dec 31, 2027 | $0.19 | $0.19 to $0.19 | 1 | $126.72M | $126.43M to $127.00M | 2 |
Quarterly Estimates
The EPS consensus rises from $0.01 for the quarter ending Dec 31, 2026 to $0.05 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.01 | $0.00 to $0.01 | 4 | $30.32M | $29.06M to $31.29M | 4 |
| Mar 31, 2027 | $0.05 | $0.05 to $0.05 | 1 | $30.11M | $30.10M to $30.13M | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has turned from a loss of $0.01 to a profit.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.10 | $0.04 | $0.04 | -$0.01 | -$0.01 | N/A |
| Fiscal year ending Dec 31, 2027 | $0.19 | $0.30 | $0.30 | $0.47 | $0.47 | -59.1% |
| Quarter ending Mar 31, 2027 | $0.05 | $0.06 | $0.06 | -$0.02 | -$0.02 | N/A |
Frequently Asked Questions About ANIK
What is the ANIK stock forecast?
Consensus analyst estimates put Anika Therapeutics's EPS at $0.10 for the fiscal year ending Dec 31, 2026, on revenue of $121.58M.
What EPS do analysts expect from ANIK next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.10, with estimates from $0.10 to $0.10 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.19, with estimates from $0.19 to $0.19 from 1 analyst.
What revenue do analysts expect from Anika Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $121.58M, with estimates from $120.70M to $122.47M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $126.72M, with estimates from $126.43M to $127.00M.
How many analysts cover ANIK?
1 analyst estimates EPS for Anika Therapeutics for the fiscal year ending Dec 31, 2026.
ANIK pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors